The Innovation Hub, a dedicated space within the virtual platform, will highlight new technologies, digital health innovation and informatics, artificial intelligence, entrepreneurship and more. This space will be used by attendees and industry representatives for interactive idea sharing, networking, imaginative business solutions and brainstorming sessions that will transform the industry.
In addition to the popular Industry-Expert Theaters and Industry Satellite Symposia, we have added Main Stage Presentations and 15-minute Lunchtime Product Demonstrations from featured exhibitors. New for this year, the Main Stage will host CEOs and CMOs of technology companies, designers, startups, key opinion leaders and business strategists. Additionally, attendees can get the latest information from exhibitors on their products during our 15-minute Lunchtime Product Demonstrations.
Main Stage Presentations
The Innovation Hub presentation content and views expressed therein are those of the company or other presenter and not of ASTRO.
Sunday, October 25
4:30 p.m. - 4:50 p.m. | Startup Company: TibaRay
Presentation Title: FLASH RT and the Development of PHASER, A Medical Linac Platform for its Clinical Translation
Speakers: Billy W. Loo Jr., MD, PhD, Cofounder and Board Member, TibaRay and Professor of Radiation Oncology, Stanford University School of Medicine
Monday, October 26
9:45 a.m. - 10:05 a.m. | Startup Company: Leo Cancer Care
Presentation Title: The Case for Upright Radiation Therapy -The topic of this presentation will be a broad look at the potential benefits that come from positioning patients in the upright
Speakers: Thomas "Rock" Mackie, PhD, Asto CT Inc.
Niek Schreuder, MSc, DABR, Leo Cancer Care Ltd.
10:10 a.m. - 10:30 a.m. | Startup Company: Cybrexa
Session Title: Breaking Through to Synergy: The Potential of DDR Inhibitors in Combination with Radiotherapy
Speakers: Ranjit Bindra, MD, PhD, Yale University
Peter Glazer, MD, PhD, Yale University
10:30 a.m. - 11:30 a.m. | Main Stage Presentation: ViewRay Inc.
Session Title: Innovation in Action: MRIdian® Solutions for Streamlining Workflow and Improving Efficiency
Speaker: Justin Rineer, MD, Orlando Heath, UF Health Cancer Center
11:30 a.m. - 11:50 a.m. | Startup Company: Concure Oncology
Session Title: One and Done - Post Pathology Radiotherapy for Early-stage Breast Cancer
Speaker: Alvaro Martinez, MD, Michigan Healthcare Professionals/Genesis Care
12:00 p.m. - 12:20 p.m. | Startup Company: bridge7
Session Title: Machine Learning-based Quality Assurance for Radiation Oncology
Speakers: Meir Dick, bridge7 Oncology
Robert Fenwick, bridge7 Oncology
Chris McIntosh, University Health Network, University of Toronto
Tom Purdie, PhD, University Health Network, University of Toronto
12:30 p.m. - 1:00 p.m. | Main Stage Presentation: Elekta
Session Title: Paradigm shifts in Precision Radiation Medicine
Speakers: Ioannis Panagiotelis, Chief Marketing & Sales Officer, Elekta
3:45 p.m. - 4:05 p.m. | Startup Company: Oncora Medical
Session Title: Deploying Machine Learning to the Cancer Clinic
Speakers: William Lindsay, CEO and Co-founder, Oncora Medical
Grace Smith, MD, Radiation Oncologist, MD Anderson Cancer Center
Tuesday, October 27
10:15 a.m. - 10:25 a.m. | Startup Company: Supportive Therapeutics
Session Title: ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer Today – A Novel Mechanistically Targeted Approach to Prevention
Speakers: Paul Song, Radiation Oncologist, Cedars-Sinai Medical Center Los Angeles, CA, USA
Daniel Osei-Fofie, Clinical and Radiation Oncologist, Kimberley Hospital Kimberley, South Africa
Stephen Sonis, Surgeon Primary Endpoint Solutions Waltham, MA and the Dana-Farber Cancer Institute Boston, MA, USA
10:30 a.m. - 10:50 a.m. | Startup Company: HPEC
Session Title: Restoring Privacy, Security and Trust to the Practice of Medicine
Speaker: Leah Houston, MD, Emergency Physician, CEO and Founder, HPEC
12:00 p.m. - 12:30 p.m. | Main Stage Presentation: Novocure
Session Title: Integrating Tumor Treating Fields (TTFields) into Radiation Practices: An Overview TTFields Dosimetry and Treatment Planning and the Potential Combination with Radiation Therapy
Speakers: Wenyin Shi, MD, PhD, Thomas Jefferson University
Matthew Ballo, MD, FACR, West Clinic Cancer Center
2:00 p.m. - 3:00 p.m. | Main Stage Presentation
Session Title: Funding
Moderator: Sameer Keole, MD, FASTRO, MD Anderson Cancer Center
Speakers: Anatha V. Santhanam, PhD, MBA, Mayo Clinic Health System Rafael Torres, Varian Medical Systems
4:15 p.m. - 4:45 p.m. | Startup Company: TheraPanacea
Session Title: AI in Radio-oncology, Reinventing Cancer Care through Powerful AI
Speakers: Prof. Nikos Paragyios, Founder and CEO, TheraPanacea
Vincent Gregoire, Chair of the Radiation Oncology Department, Centre Léon Bérard
Eric Deutsch, Head of the Radiotherapy Department, Institute Gustave Roussy
Thais Roque, Research and Clinical Partnerships Manager, TheraPanacea
Wednesday, October 28
12:00 p.m. - 1:00 p.m. | Main Stage Presentation
Session Title: Early Startup Experience
Moderators: David Jaffray, PhD, MD Anderson Cancer Center
Steven Frank, MD, MD Anderson Cancer Center
Speakers: Thomas Rock Mackie, PhD, Morgridge Institute for Research
John R. Adler, MD, Stanford University
2:00 p.m. - 3:00 p.m. | Main Stage Presentation
Session Title: Early Interactions with FDA: The Pre-submission Program
Moderator: Shilpen Patel, MD, FASTRO, Sutter Health
Panelists: John Nicholas Grimes, PhD, Vanderbilt University
Cindy Tomlinson, MPP, ASTRO
Nancy Wersto, Food and Drug Administration
3:45 p.m. - 4:45 p.m. | Main Stage Presentation: Varian Medical Systems
Session Title: Varian Innovation: Pioneering for the Future
Speakers: Deepak Khuntia, MD, Varian Medical Systems
Sasa Mutic, PhD, Varian Medical Systems
Corey Zankowski, PhD, Varian Medical Systems
And the other 10,000 Varian employees
Industry-Expert Theaters
The Industry-Expert Theater content and views expressed therein are those of the Exhibitor and not of ASTRO.
Sunday, October 25
12:00 p.m. – 1:00 p.m. | AstraZeneca
Presentation Title: Treatment in Unresectable Stage III Non-Small Cell Lung Cancer
Treatment for Unresectable Stage III NSCLC Following Concurrent Chemoradiation Therapy
Speaker: Alexander C. Whitley, MD, PhD, FACRO, Medical Director, Central Alabama Radiation Oncology, Montgomery, AL
This session will not be recorded and will only be available during the date and time listed.
Monday, October 26
11:00 a.m. – 12:00 p.m. | Brainlab
Presentation Title: First Clinical Applications of Exactrac Dynamic
To register in advance for this Industry-Expert Theater session, please visit https://novalis-circle.easywebinar.live/registration-142.
Radiosurgical Planning: Brain and Spine Disease Considerations
Speaker: Maximilian Niyazi, MD, LMU Hospital Munich, Germany
IGRS Experience: Intra-cranial Tumors and Spine Metastasis Setups
Speaker: Philipp Freislederer, MS, LMU Hospital Munich, Germany
Radiotherapy Planning: Breast Disease Considerations
Mark De Ridder, MD, PhD, UZ Brussel, Belgium
IGRT Experience: Free-Breathing and Manual Breath-hold Breast Setups
Thierry Gevaert, PhD, UZ Brussel, Belgium
11:00 a.m. – 12:00 p.m. | Bristol Myers Squibb
Presentation Title: Investigating the Potential of Immuno-Oncology Research
This session will not be recorded and will only be available during the date and time listed.
12:00 p.m. – 1:00 p.m. | CIVCO Radiotherapy
Presentation Title: Stereotactic Setups and Treatments: A Clinical Perspective
This presentation examines the common challenges and important clinical considerations that must be met when performing patient setups for stereotactic treatments. Particular focus will be given to cranial SRS and SBRT, and the heightened setup demands that accompany these treatments. Clinical guest speakers share their experiences of working with CIVCO positioning devices in the stereotactic environment, and tips and techniques for device and patient setup are demonstrated. Planning considerations are also addressed, and two studies that highlight the efficacy of a novel positioning device are discussed.
Speakers: Sean Santoscoy - RT(T) Product Specialist, CIVCO Radiotherapy
Bill Barnat, Product Specialist, Research and Development, CIVCO Radiotherapy
Chin Loon Ong Medical Physicist Haga Hospital, Netherlands
Luis Madureira, Clinical Education and Training Manager, Medical Physics, CIVCO Radiotherapy
Amanda Jasek - BSRT (R)(T) Clinical Applications Specialist, CIVCO Radiotherapy
Dawn DeBartolo, BSRT (T) Clinical Applications Specialist, CIVCO Radiotherapy
Ben Allen, Technical Lead Radiographer QEH, Birmingham
12:00 p.m. – 1:00 p.m. | Novocure Inc.
Presentation Title: Tumor Treating Fields: Translating Science into Practice
Objectives:
- Provide an overview of the mechanism of action of Tumor Treating Fields (TTFields) and evidence for activity in tumor cells
- Share clinical trial experience with TTFields supporting its application in glioblastoma and malignant pleural mesothelioma (MPM)
Speakers: Dr. Pavan Jhaveri, Associate Professor, Medical Director, Department of Radiation Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Dr. Samir P. Kanani, George Washington University
Tuesday, October 27
11:00 a.m. – 12:00 p.m. | ViewRay, Inc.
Presentation Title: Maximizing Clinical Value of MRIdian – Dana-Farber/Brigham Women’s Cancer Center
12:00 p.m. – 1:00 p.m. | Janssen Biotech, Inc.
Presentation Title: ERLEADA: TITAN and New Data for SPARTAN Final Analysis
Speakers: Dr. Steven Finkelstein, Florida Cancer Affiliates (The US Oncology Network)
Dr. David Crawford, University of San Diego California
This session will not be recorded and will only be available during the date and time listed.
Wednesday, October 28
11:00 a.m. – 12:00 p.m. | Seattle Genetics
Presentation Title: TUKYSA® (tucatinib): A Treatment Option for patients with HER2+ metastatic breast cancer (MBC)
Speaker: Rebecca Lynn Moroose, MD
This session will not be recorded and will only be available during the date and time listed.
11:00 a.m. - 12:00 p.m. | ASTRO Expert Theater
Presentation Title: Code Development and Valuation: What Radiation Oncology Industry Stakeholders Need to Know
Radiation oncology is a dynamic and innovative field. Industry stakeholders frequently come to ASTRO with questions regarding coding and valuation for new technologies and services. This is an opportunity to hear from ASTRO’s experts about the process, what’s involved and why collaboration is critical.
ASTRO Experts:
Amar Rewari, MD, MBA – Dr. Rewari serves as a member of ASTRO’s Code Development and Valuation Committee. He is also ASTRO’s RUC Alternate Advisor.
Catheryn Yashar, MD – Dr. Yashar serves as a member of ASTRO’s Code Development and Valuation Committee. She is also ASTRO’s CPT Alternate Advisor
Bryan Hull, Esq., MPH – Mr. Hull is ASTRO’s Assistant Director of Health Policy. He serves as the staff liaison to the Code Development and Valuation Committee, as well as the key staff point person for ASTRO’s CPT and RUC activities.
Industry Satellite Symposia
The American Society for Radiation Oncology (ASTRO) has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium. The symposium constitutes the content and views of the provider and is not part of the official ASTRO Annual Meeting program.
Saturday, October 24
5:00 p.m. - 5:30 p.m. | Session Title: TARGIT-A Survival and Local Control Outcomes as a Single IORT Fraction- Randomized Controlled Phase III Long Term Results
This is a Non-CME informational activity designed for radiation oncologists, medical physicists, surgical oncologists, breast surgeons, hospital administrators, radiotherapy administrators, radiotherapists, nurse navigators and cancer program administrators. No CME is offered for this program.
Learning Objectives:
- Understand the TARGIT-A IORT protocol for single-fraction radiotherapy for low-risk lumpectomy cases and IORT boost radiotherapy for higher-risk lumpectomies.
- Understand the TARGIT-A study design and statistical validity of the data represented.
- Learn about the risk-adapted approach to the TARGIT-A protocol.
- Learn about patient selection for x-ray IORT.
- Review and compare the results of the long-term data for overall survival and local control.
This activity is hosted by Carl Zeiss.
Sunday, October 25
5:00 p.m. - 6:30 p.m. | Session Title: Optimizing Care in Lung Cancer: Current and Emerging Biomarkers for Immuno-Oncology
Joint Accreditation Statement:
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education:
CCO designates this live activity for a maximum of 1.5
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience:
This program is intended for radiologists, medical oncologists, and other healthcare providers who care for patients with lung cancer.
Learning Objectives:
- Upon completion of this activity, participants should be able to:
- Apply new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
- Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
- Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
- Consider patients for enrollment in clinical trials investigating novel therapeutic approaches, including neoadjuvant/adjuvant immunotherapy in lung cancer
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Sunday, October 25
5:45 p.m. - 6:45 p.m. | Session Title: Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancers: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy
For more information and to register, please visit
PeerView.com/RadOnc2020
Accreditation:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute Inc. is accredited by the ACCME to provide continuing medical education for physicians.
CME Credits:
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience:
This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, surgical oncologists, and other clinicians involved in the management of interdisciplinary, multimodal management of patients with esophageal or gastroesophageal junction cancer.
Learning Objectives:
- Describe the mechanisms by which immunotherapies harness the immune system in the treatment of esophageal and gastroesophageal junction (GEJ) cancers and the rationale for using immune checkpoint inhibition as adjuvant therapy in locally advanced and earlier-stage disease
- Evaluate the latest clinical trials and data related to the use of adjuvant immunotherapy in locally advanced and earlier stages of esophageal or GEJ cancer
- Develop optimal multidisciplinary treatment plans for patients with locally advanced and earlier- stage esophageal or GEJ cancer, including clinical trial enrollment, based on the available evidence, patient- and disease-related factors, and expert recommendations
This activity is supported through an educational grant from Bristol Myers Squibb.
Tuesday, October 27
5:30 p.m. - 6:30 p.m. | Session Title: Modernizing Your Radiation Oncology Practice With Tumor Treating Fields and Other Novel Multimodal Strategies: Understanding the Science, Evidence, and Practical Aspects Across a Range of Solid Tumors
For more information and to register, please visit
PeerView.com/RadOnc20
Accreditation:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
CME Credits:
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience:
This activity has been designed to meet the educational needs of radiation oncologists and other clinicians involved in the management of interdisciplinary, multimodal management of patients with solid tumors.
Learning Objectives:
- Summarize the mechanistic rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy
- Evaluate the key safety and efficacy evidence on innovative strategies available for the therapeutic management of GBM and MPM
- Review the most recent evidence and ongoing clinical trials on novel therapeutic modalities, including combining TTFields with systemic therapy, radiotherapy, or other modalities, in multiple tumor types such as lung, pancreatic, gastric, liver, and ovarian cancers, across different treatment settings
- Develop strategies to effectively integrate novel technologies into the therapeutic management of patients with cancer, including through appropriate adverse event management and enrollment in clinical trials
This activity is supported by an educational grant from Novocure.